ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "anti-TNF therapy"

  • Abstract Number: 564 • 2019 ACR/ARP Annual Meeting

    ASDAS Is More Important Than BASDAI in Advanced Ankylosing Spondylitis

    Jae-Bum Jun1, Bon San Koo 2, Seunghun Lee 3, Jinju Kim 4, Juyeon Kang 1 and Tae-Hwan Kim 1, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 2Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea, 3Dertment of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 4Novartis Korea Ltd., Seoul

    Background/Purpose: In patients with ankylosing spondylitis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to measure disease activity to initiate or maintain TNF…
  • Abstract Number: 1446 • 2019 ACR/ARP Annual Meeting

    Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany

    Klaus Krüger 1, Gerd Burmester 2, Siegfried Wassenberg 3, Astrid Thiele 4 and Matthias Thomas5, 1Medical Centre of Rheumatology, Munich, Germany, 2Charité—University Medicine Berlin, Berlin, Germany, 3Centre of Rheumatology, Ratingen, Germany, 4Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, 5MSD Sharp & Dohme GmbH, Haar, Germany

    Background/Purpose: The aim of this post hoc analysis is to assess effectiveness of GLM used as first, second, or at least third biologic agent in…
  • Abstract Number: 2768 • 2019 ACR/ARP Annual Meeting

    Changes in B Cell Profile as a Marker of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis

    Borja Hernández-Breijo1, Israel Nieto-Gañán 2, Cristina Sobrino 3, Victoria Navarro-Compán 4, Ana Martínez-Feito 5, Carlota García-Hoz 6, Paloma Lapuente-Suanzes 2, javier Bachiller 3, Gema Bonilla 7, Cristina Pijoán-Moratalla 3, Garbiñe Roy 2, Mónica Vázquez Díaz 3, Alejandro Balsa 7, Luisa María Villar 2, Dora Pascual-Salcedo 1, Eulalia Rodríguez-Martín 2 and Chamaida Plasencia 7, 1Immuno-Rheumatology Research Group, IdiPAZ. La Paz University Hospital, Madrid, Spain, 2Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, 3Rheumatology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, 4University Hospital La Paz, IdiPaz, Madrid, Spain, 5Immuno-Rheumatology Research Group, IdiPAZ & Immunology Department. La Paz University Hospital, MADRID, Spain, 6Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, 7Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain

    Background/Purpose: According to the EULAR recommendations, the therapeutic objective in patients with rheumatoid arthritis (RA) should be remission. Biological therapies, as TNF inhibitors (TNFi), have…
  • Abstract Number: 571 • 2019 ACR/ARP Annual Meeting

    Effect of Long-term Treatment with TNF-α Inhibitor on Lipid Profile in Spondyloarthritis: Data from Nationwide Korean College of Rheumatology Biologics (KOBIO) Registry

    Jina Yeo1, Mi Ryoung Seo 1, Hee Jung Ryu 1, Hyo-Jin Choi 1 and Han Joo Baek 1, 1Division of Rheumatology / Department of Internal Medicine / Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea

    Background/Purpose: In spondyloarthritis (SpA), the lipid profile changes due to the systemic inflammatory response. Theoretically, the proinflammatory state is associated with a decrease in total…
  • Abstract Number: 1476 • 2019 ACR/ARP Annual Meeting

    Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits

    Lynn Price1, Phil Pouliot 1 and Lauren Schmitt 1, 1Spherix Global Insights, Exton, PA

    Background/Purpose: TNF-α inhibitor therapy has long been the standard of care for adult patients diagnosed with moderate to severe psoriatic arthritis (PsA), though several new…
  • Abstract Number: 2856 • 2019 ACR/ARP Annual Meeting

    Drug Retention of Biological DMARDs Targeting IL-12/IL-23 or IL-17 versus TNF Inhibitors, After a First Line TNF Inhibitor, in Patients with Psoriatic Arthritis – an Analysis in the Swiss SCQM Register

    Burkhard Moeller1, Eleftherios Papagiannoulis 2, Lisa Christ 3, Adrian Ciurea 4, Thomas Hugle 5, Ruediger B. Mueller 6, Michael J. Nissen 7, Almut Scherer 8, Godehard Scholz 3, Peter M. Villiger 1 and Nikhil Yawalkar 3, 1University Hospital Bern, Bern, Switzerland, 2SCQM Zurich, Zurich, Switzerland, 3Inselspital-University Hospital Bern, Bern, Switzerland, 4University Hospital Zürich, Zürich, Switzerland, 5University Hospital Lausanne, Lausanne, Switzerland, 6Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, 7University Hospital Geneva, Geneva, Switzerland, 8SCQM Foundation, Zürich, Switzerland

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) were the first approved biological disease modifying antirheumatic drugs (bDMARDs) for psoriatic arthritis (PsA). IL-12/23 and IL-17-specific antibodies provide…
  • Abstract Number: 581 • 2019 ACR/ARP Annual Meeting

    Allograft Inflammatory factor-1 Drives Th17 Like Pathologic Signature and Predict Poor Response to TNF Inhibitor in Ankylosing Spondylitis

    Jeong Seok Lee1, Eunyoung Lee 2, Ji Yong Choi 3, Yeong-Wook Song 4, Eui-Cheol Shin 1 and Eun Young Lee 2, 1Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea, 3Seoul National University College of Medicine, Seoul, Republic of Korea, 4Seoul National University Hospital, Seoul, Republic of Korea

    Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory disease that commonly treated with TNF inhibitors for controlling active inflammation. To predict treatment response to TNF inhibitors…
  • Abstract Number: 1499 • 2019 ACR/ARP Annual Meeting

    Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study

    René-Marc Flipo 1, Florence Tubach 2, Jean Ouaniche 3, Philippe Goupille4, Eric Lespessailles 5, Najat Gouyette 6, Naoual Harid 7, Jean-Marie Fayette 8, Philippe Bertin 9 and Bruno Fautrel 10, 1Roger Salengro University-Hospital, Lille , France, Lille, France, 2Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, 3Private Practice , Toulon, France, Toulon, France, 4Tours University-Hospital, Tours, France, Tours, France, 5Orléans Regional Hospitals, Orléans ,France, Orléans, France, 6MSD France, Courbevoie ,France, Courbevoie, Ile-de-France, France, 7MSD France, Courbevoie, France, Courbevoie, Ile-de-France, France, 8ClinSearch, Malakoff, France, Malakoff, Ile-de-France, France, 9Limoges University-Hospital , Limoges, France, Limoges, France, 10Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France

    Background/Purpose: The pivotal GO AFTER study [1] and the ongoing observational GO BEYOND study investigate GLM efficacy in rheumatoid arthritis (RA) patients who previously received…
  • Abstract Number: 2857 • 2019 ACR/ARP Annual Meeting

    Decision Tree Analysis to Identify Inflammatory Arthritis Patient Subgroups with Different Levels of Treatment Persistence with First-Line Subcutaneous TNF-alpha Inhibitors

    Emma Hernlund 1, Johan Klint 1, Axel Svedbom 1, Johan Dalén 1, Christopher Black 2 and Amy Puenpatom2, 1ICON plc, Stockholm, Sweden, Stockholm, Sweden, 2Merck & Co., Inc., Kenilworth, NJ, United States, Kenilworth, NJ

    Background/Purpose: The advent of biologic medications, such as subcutaneous TNF-alpha inhibitors (SC-TNFi), has transformed the management of inflammatory arthritis (IA) during the last decades. However,…
  • Abstract Number: 619 • 2019 ACR/ARP Annual Meeting

    Relation of Therapies for Ankylosing Spondylitis to Risk of Total Hip and Knee Arthroplasty

    Rachael Stovall1, Christine Peloquin 2, David Felson 3, Tuhina Neogi 2 and Maureen Dubreuil 4, 1Boston Medical Center, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3Boston University School of Medicine, Department of Rheumatology, Boston, 4Boston University School of Medicine, Boston

    Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory arthritis that predominantly affects the axial skeleton, but commonly affects peripheral joints as well. Peripheral joint involvement often…
  • Abstract Number: 1512 • 2019 ACR/ARP Annual Meeting

    Retention Rates and Response of Anti-TNF Treatments in the Enteropathic Spondylitis: HUR-BIO Real Life Results

    Gozde Kubra Yardımcı 1, Bayram Farisoğulları 1, Alper Sarı 1, Levent Kilic 2, Berkan Armagan 3, Emre Bilgin 1, Ertugrul Cagri Bolek 1, Omer Karadag 4, Ali Akdoğan 1, Şule Apras Bilgen 2, Ali İhsan Ertenli 1, Sedat Kiraz 2 and Umut Kalyoncu5, 1Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, 2Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 3Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, 4Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey, 5Hacettepe University Department of Rheumatology, Ankara, Turkey

    Background/Purpose: Enteropathic spondylitis (eSpA) is younger brother of spondyloarthritis, and the retention rate of biological DMARD in eSpA was not yet clear.  The objective of this study was to…
  • Abstract Number: 2873 • 2019 ACR/ARP Annual Meeting

    Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland

    Aron H Bjornsson1, Olafur Palsson 2, Mar Kristjansson 3, Petur S Gunnarsson 4, Gerdur Grondal 5, Bjorn Gudbjornsson 6 and Thorvardur J Love 7, 1Department of Medicine, Landspitali, Reykjavík, Iceland, 2Department of Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden, 3Department of Infectious Diseases, Landspitali, Reykjavík, Iceland, 4Faculty of Pharmaceutical Sciences, University of Iceland and Hospital Pharmacy, Landspitali, Reykjavík, Iceland, 5Department of Rheumatology, Landspitali and Centre for Rheumatology Research, Landspitali, Reykjavík, Iceland, 6Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 7Faculty of Medicine, University of Iceland and Department of Science, Landspitali, Reykjavík, Iceland

    Background/Purpose: Severe infections, frequently resulting in hospitalization, are a well-known adverse effects of tumor necrosis factor inhibitors (TNFi). However, studies regarding outpatient treated infections are…
  • Abstract Number: 933 • 2019 ACR/ARP Annual Meeting

    Tumor Necrosis Factor Inhibitors Slow Radiologic Progression in Patients with Ankylosing Spondylitis: 18-year Longitudinal Cohort Study

    Bon San Koo1, Ji Seon Oh 2, Seo Young Park 3, Ga Young Ahn 4, Seunghun Lee 5, Kyung Bin Joo 6 and Tae-Hwan Kim 7, 1Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea, 2Department of Biomedical Informatics, Asan Medical Center, Seoul, Korea, Seoul, Republic of Korea, 3Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul-t'ukpyolsi, Republic of Korea, 4Korea University Guro Hospital, Seoul, Republic of Korea, 5Dertment of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 6Department of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Seoul-t'ukpyolsi, Republic of Korea, 7Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea

    Background/Purpose: It is difficult to evaluate the role of TNF inhibitor therapy in slowing the radiologic progression in patients with ankylosing spondylitis (AS) because of…
  • Abstract Number: 1518 • 2019 ACR/ARP Annual Meeting

    Tumour Necrosis Factor Inhibitor Monotherapy versus Combination Therapy with Conventional Synthetic Disease-modifying Anti-rheumatic Drugs for the Treatment of Psoriatic Arthritis: A Combined Analysis of European Biologics Databases

    Matthew Thomas 1, Gavin Shaddick 2, Rachel Charlton 1, Charlotte Cavill 3, Richard Holland 4, Florenzo Iannone 5, Giovanni Lapadula 6, Simona Lapriore 5, Jakub Závada 7, Michal Uher 8, Karel Pavelka 9, Lenka Szczukova 10, Prodromos Sidiropolous 11, Irini Flouri 11, Burkhard Moeller 12, Michael J. Nissen 13, Ruediger B. Mueller 14, Almut Scherer 15, Neil McHugh1 and Alison Nightingale 1, 1University of Bath, Bath, United Kingdom, 2University of Exeter, Exeter, United Kingdom, 3Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, United Kingdom, 4Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 5University of Bari, Bari, Italy, 6Rheumatology Unit – Department of Emergency and Organs Transplantation, University and AOU Policlinico of Bari, Italy., Bari, Italy, 7Institute of Rheumatology, Prague, Prague, Czech Republic, 8Institute of Health Information and Statistics of the Czech Republic, and Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic, 9Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 10Masaryk University, Brno, Czech Republic, 11University of Crete, Crete, Greece, 12University Hospital Bern, Bern, Switzerland, 13University Hospital Geneva, Geneva, Switzerland, 14Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, 15SCQM Foundation, Zürich, Switzerland

    Background/Purpose: A large proportion of psoriatic arthritis (PsA) patients are prescribed a tumour necrosis factor inhibitor (TNFi) in combination with methotrexate (MTX), however the value…
  • Abstract Number: 935 • 2019 ACR/ARP Annual Meeting

    Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis Following 1 Year of Treatment with Certolizumab Pegol: 48-Week Interim Results from a 96-Week Open-Label Study

    Irene van der Horst-Bruinsma1, Rianne van Bentum 1, Frank D. Verbraak 1, Thomas Rath 2, James T. Rosenbaum 3, Maria Misterska-Skóra 4, Bengt Hoepken 5, Oscar Irvin-Sellers 6, Brenda VanLunen 7, Lars Bauer 5 and Martin Rudwaleit 8, 1Amsterdam University Medical Center, Amsterdam, Netherlands, 2St Franziskus-Hospital, Münster, Germany, 3Devers Eye Institute and Oregon Health & Science University, Portland, OR, 4Wrocław Medical University, Wrocław, Poland, 5UCB Pharma, Monheim am Rhein, Germany, 6UCB Pharma, Slough, UK, Slough, United Kingdom, 7UCB Pharma, Raleigh, NC, 8Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany

    Background/Purpose: Acute anterior uveitis (AAU), inflammation of the anterior uveal tract, is the most common extraarticular manifestation in patients (pts) with axial spondyloarthritis (axSpA), reported…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology